Our Story
Intensity Therapeutics is a clinical-stage biotechnology company whose mission is to help patients live longer, higher quality lives by discovering, developing, and commercializing first-in-class cancer drugs that attenuate tumors with minimal side effects, while training the patient’s own immune system to fight the cancer.
Our lead product candidate, INT230-6, is currently in human clinical studies to treat refractory solid tumors.
A Bold, New Treatment Approach for Cancer
Treat locally, act globally.
Our company was founded in 2012 with the understanding that solid tumor cancers consist of well-defined visible growths and unseen micro-metastases.
Cancer is thus both a regional and a systemic disease. To treat cancer effectively, both the existing large observable tumors as well as all the unseen cell-level micrometastases (which can be anywhere in the body), must be destroyed (or removed). Our unique products are clear, 100% water solutions and NOT nanoparticles, liposomes or emulsions.
A Bold, New Treatment Approach for Cancer
Treat locally, act globally.
Our Company was founded in 2012 with the understanding that solid tumor cancers consist of well-defined visible growths and unseen micro-metastases.
Cancer is thus both a regional and a systemic disease. To treat cancer effectively, both the existing large observable tumors as well as all the unseen cell-level micrometastases (which can be anywhere in the body), must be destroyed (or removed). Our unique products are clear, 100% water solutions and NOT nanoparticles, liposomes or emulsions.
Our novel approach treats both the macro and the micro aspects of cancer.
When injected intratumorally (dosed locally), our products have high tumor dispersion and cell penetration properties. These injected products directly kill the tumor cells. This localized cell death results in the creation of antigenic sites that stimulate the adaptive immune system (act globally). The elicited immune response helps to destroy or regress the injected tumor, while also eliminating secondary tumors and micrometastases.
Using our DfuseRxSM platform technology, we can create novel cell penetrating formulations of anti-cancer agents for a given cancer type. Our first product candidate uses proven cytotoxic agents. In clinical studies, our therapies have demonstrated an ability to induce tumor necrosis and regress both injected and uninjected tumors – known as an abscopal effect. In addition, our studies have shown that 95% of the active ingredients in our drug remain in the injected tumor, helping to avoid off-target systemic toxicities.
History
In 2012, our founder recognized that the more fluid nature of cancer cell membranes vis a vis healthy tissue, could be exploited using a new drug delivery technology. In less than five years, that simple idea led to a company with a new drug in clinical trials under both a U.S. FDA Investigational New Drug (IND) and a Health Canada Clinical Trial Application (CTA). Since 2017, over 200 patients have been enrolled in two clinical trials with a phase 3 registration study in soft tissue sarcoma now being planned.